Fig. 4: The absence of BCL-W has no impact on the survival of lymphoma-derived cell lines after treatment with BH3-mimetic drugs. | Oncogene

Fig. 4: The absence of BCL-W has no impact on the survival of lymphoma-derived cell lines after treatment with BH3-mimetic drugs.

From: BCL-W makes only minor contributions to MYC-driven lymphoma development

Fig. 4

A, B Results from independent lymphoma-derived cell lines from five of each of Eµ-MycT/+;Bcl-w+/+, Eµ-MycT/+;Bcl-w+/−, or Eµ-MycT/+;Bcl-w−/− mice, examined for their viability after treatment for 24 h with the indicated BH3-mimetic drugs. No differences in viability were observed between lymphoma cell lines of the different genotypes, regardless of whether (A) S63845 (inhibitor of MCL-1) or (B) ABT-737 (inhibitor of BCL-2 + BCL-XL + BCL-W) was used. In addition, while S63485 was able to robustly induce death in the lymphoma cells, these cells were largely resistant to treatment with ABT-737.

Back to article page